SMARCE1: A Potential Drug Target and Biomarker for Chromatin Remodeling and Maintenance

Target Name: SMARCE1

NCBI ID: G6605

SMARCE1

Other Name(s): Chromatin remodeling complex BRG1-associated factor 57 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin e1 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 | BAF57 | CSS5 | chromatin remodeling complex BRG1-associated factor 57 | SMCE1_HUMAN | BRG1-associated factor 57

SMARCE1: A Potential Drug Target and Biomarker for Chromatin Remodeling and Maintenance

Introduction

Chromatin remodeling complexes (CRCs) play a crucial role in the regulation of gene expression and are involved in various cellular processes, including DNA replication, repair, and maintenance. The Chromatin remodeling complex (BRG1-associated factor 57, SMARCE1) is a protein that is involved in the regulation of CRCs and has been identified as a potential drug target and biomarker.

SMARCE1: Structure and Function

SMARCE1 is a 25kDa protein that is composed of 192 amino acid residues. It has a molecular weight of 21.9 kDa and a calculated pI of 6.5. SMARCE1 is localized to the nucleosome and is associated with the BRG1 complex, which is a critical complex for regulating DNA replication in eukaryotic cells.

The BRG1-associated factor 57 (BAF57) complex is a protein complex that is composed of the protein SMARCE1, the nucleosome chaperone BAF115, and the DNA-binding proteinSMARCE3. The BRG1-associated factor 57 complex plays a role in the regulation of DNA replication by allowing the access of the nucleosome chaperone BAF115 to the replication complex.

SMARCE1 has been shown to play a critical role in the regulation of CRCs by promoting the association of the BRG1-associated factor 57 complex with the nucleosome. It has been shown that SMARCE1 promotes the recruitment of BAF57 to the nucleosome and that this association is necessary for the recruitment of SMARCE2 to the nucleosome.

SMARCE1 has also been shown to play a role in the regulation of gene expression by controlling the levels of histone H3A.2a on the nucleosome. It has been shown that the levels of H3A.2a on the nucleosome are regulated by SMARCE1, and that these levels are involved in the regulation of gene expression.

SMARCE1 and Cancer

SMARCE1 has been shown to be involved in the regulation of cancer development and progression. For example, it has been shown that high levels of SMARCE1 are associated with the development of pancreatic cancer. Additionally, it has been shown that SMARCE1 is involved in the regulation of the growth and survival of cancer cells.

SMARCE1 has also been shown to be involved in the regulation of the development and progression of neurodegenerative diseases. For example, it has been shown that SMARCE1 is involved in the regulation of the translation of the neurodegenerative disease-causing gene, SMARTC.

SMARCE1 as a Potential Drug Target

SMARCE1 has been identified as a potential drug target due to its involvement in the regulation of CRCs and its association with various diseases. Currently, there are no FDA-approved drugs that specifically target SMARCE1. However, there are several small molecules that have been shown to interact with SMARCE1 and may be potential drug candidates.

One of the most promising small molecules is a compound called RXR1012, which is a selective inhibitor of SMARCE1. RXR1012 has been shown to be effective in cell experiments in vitro and in animal models of disease.

Another small molecule that has been shown to interact with SMARCE1 is the drug sunitinib, which is an inhibitor of the kinase PD-L1. Sunitinib has been shown to be effective in

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1

Functions: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Required for the coactivation of estrogen responsive promoters by SWI/SNF complexes and the SRC/p160 family of histone acetyltransferases (HATs). Also specifically interacts with the CoREST corepressor resulting in repression of neuronal specific gene promoters in non-neuronal cells

The "SMARCE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets